These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 26468555)
21. Dilemmas in drug therapy. Kayser SR Prog Cardiovasc Nurs; 1997; 12(4):29-31, 33. PubMed ID: 9433731 [No Abstract] [Full Text] [Related]
22. Cardiovascular research is thriving in China. Gao F; Sun RJ; Ji Y; Yang BF Br J Pharmacol; 2015 Dec; 172(23):5430-4. PubMed ID: 24962428 [TBL] [Abstract][Full Text] [Related]
23. Recent Advances in the Discovery and Development of Marine Natural Products with Cardiovascular Pharmacological Effects. Zhou JB; Luo R; Zheng YL; Pang JY Mini Rev Med Chem; 2018; 18(6):527-550. PubMed ID: 28969542 [TBL] [Abstract][Full Text] [Related]
24. Periprocedural risk of bleeding and thrombosis: to bridge or not to bridge. Dr. James Douketis in an interview with Dr. Roman Jaeschke: part 2. Douketis J; Jaeschke R Pol Arch Med Wewn; 2016 Oct; 126(10):801-802. PubMed ID: 27872458 [No Abstract] [Full Text] [Related]
25. Drugs acting on blood and/or blood forming organs. Boothe DM Vet Clin North Am Small Anim Pract; 1998 Mar; 28(2):329-60. PubMed ID: 9556851 [TBL] [Abstract][Full Text] [Related]
29. [On the therapeutic use of vitamin E in clinical medicine: motivations and prospects]. Butturini U Acta Vitaminol Enzymol; 1977; 31(1-5):125-42. PubMed ID: 580682 [No Abstract] [Full Text] [Related]
30. Thymidine phosphorylase: A potential new target for treating cardiovascular disease. Li W; Yue H Trends Cardiovasc Med; 2018 Apr; 28(3):157-171. PubMed ID: 29108898 [TBL] [Abstract][Full Text] [Related]
31. Advances in cardiovascular pharmacology. Hayes AH JAMA; 1982 Aug; 248(5):537-43. PubMed ID: 7097893 [No Abstract] [Full Text] [Related]
32. The impact of molecular medicine upon early cardiovascular drug development. Lunnon MW; Braddock M Br J Clin Pharmacol; 2000 Jul; 50(1):1-8. PubMed ID: 10886110 [No Abstract] [Full Text] [Related]
33. Lipid-lowering drugs. Med Lett Drugs Ther; 2016 Oct; 58(1506):133-140. PubMed ID: 27755510 [No Abstract] [Full Text] [Related]
34. Clinical Implementation of Cardiovascular Pharmacogenomics. Pereira NL; Stewart AK Mayo Clin Proc; 2015 Jun; 90(6):701-4. PubMed ID: 26046404 [No Abstract] [Full Text] [Related]
35. The US Food and Drug Administration and Cardiovascular Medicine: Reflections and Observations. Califf RM Circulation; 2016 Aug; 134(7):501-3. PubMed ID: 27528644 [No Abstract] [Full Text] [Related]
36. Data Mining as a Powerful Tool for Creating Novel Drugs in Cardiovascular Medicine: The Importance of a "Back-and-Forth Loop" Between Clinical Data and Basic Research. Kitakaze M; Asakura M; Nakano A; Takashima S; Washio T Cardiovasc Drugs Ther; 2015 Jun; 29(3):309-15. PubMed ID: 26095683 [TBL] [Abstract][Full Text] [Related]
37. Opinion and evidence in cardiovascular therapeutics. Am J Cardiovasc Drugs; 2003; 3(2):139-48. PubMed ID: 14727940 [TBL] [Abstract][Full Text] [Related]
38. [Psychotropic drugs in internal medicine. III. Uses and indications in non-psychiatric patients]. de la Fuente JR; Nieto Caraveo A Rev Invest Clin; 1987; 39(3):255-61. PubMed ID: 2893440 [No Abstract] [Full Text] [Related]
40. In vitro diagnostics in the development and use of cardiovascular medicines. Leadley RJ Curr Opin Mol Ther; 2010 Dec; 12(6):639-46. PubMed ID: 21154155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]